Sea Lane Biotechnologies, LLC

The SEA LANE BIOTECHNOLOGIES fully human bio-therapeutic platform technologies provide unique solutions for pressing therapeutic needs. Our technologies and inventions include the therapeutic class of entities known as Surrobodies™ and world-class human antibody libraries.  Each represents a bio-therapeutic platform which may be leveraged externally, via partnerships, or through internal discovery and development efforts to meet the rigorous requirements of creating a competitive product candidate pipeline and portfolio. Located in the Silicon Valley, Sea Lane stands out as a premier biotech company dedicated to creating truly innovative bio-therapeutic approaches, and building value on top of those foundations of discovery. 

 

 

 

News

Sea Lane and Takeda announce multi-year, multi-target discovery license agreement for the use of Sea Lane’s ConCIRT libraries and technology Read More

 

Sea Lane and Sanford Burnham present poster at AACR Conference in Washington DC April 6-10, 2013 Download Poster

 

Ramesh Bhatt Presents at IBC's Antibody-Drug Conjugates, Bispecifics & Empowered Antibodies Summit August 8, 2012

Click here for the slides

 

Sea Lane Biotechnologies Successfully Generates and Delivers Therapeutic Candidates In Discovery Research Collaboration with Agensys, Inc., an Affiliate of Astellas Pharma Inc. Read More

 

Sea Lane presents poster at PEGS Conference in Boston, April 30 - May 4 Download Poster

 

Sea Lane announces the granting of three US patents covering Surrobody technology, synthetic antibody library design and human derived libraries

Influenza paper published in Nature Sept 16, 2012

Read More

 

ErbB3 Surrobody paper published in Molecular Cancer Therapeutics

Read More

 

Influenza paper Published in PLoS Pathogens

Read More

 

Surrobody™ Paper Published in JMB

Read More

 

Surrobody™ Paper Published in PNAS
Read More

 

© 2010, Sea Lane Biotechnologies, LLC.  All Rights Reserved.